FDA Tells Court It Expects Mifepristone Safety Study Results by December and a Final Report by March 2027, With Telehealth Prescribing Unchanged for Now

The Food and Drug Administration has given a federal court its first detailed timetable for the safety review that could reshape how mifepristone, one of two drugs used in medication abortion, reaches patients. In a court-ordered status report filed late on October 7, 2026, the agency said it expects to complete its safety study of the drug by mid-December 2026 and to issue a report on the findings no later than March 2027. Only after that report, the FDA said, will it decide whether to change the rules for prescribing and distributing mifepristone, including the 2023 decision that made telehealth prescribing and mail delivery practical.

What the FDA told the court

The filing was a progress update, not a conclusion. A federal judge in Louisiana had ordered the government to report on where the review stood, and the Justice Department, representing the FDA, submitted the status report on the agency's behalf. The FDA set out a two-step timeline, with a decision on the drug's rules to come only afterward.

• Mid-December 2026: the FDA expects to finish the underlying safety study of mifepristone.
• No later than March 2027: the FDA expects to analyze the data and issue a report evaluating the results.
• After the report: the agency says it will decide whether to change how mifepristone is prescribed and distributed, including whether to impose new restrictions.

What the review is examining

The review targets the drug's Risk Evaluation and Mitigation Strategy (REMS), the federal safety program that governs how mifepristone is prescribed and dispensed. Reporting on the filing describes two lines of analysis: the FDA is comparing the safety profile of medication abortion with that of surgical abortion through 10 weeks of gestation, measuring how often side effects occur among roughly 100,000 women who took the drug, and it is using a statistical data-mining method to scan databases of medical injury and side-effect reports from health networks and insurers for safety signals it may not have identified before. The agency said it is also weighing petitions that ask it to change how the drug is prescribed and distributed.

Why the 2023 change matters for telehealth

The REMS is the regulatory foundation for remote prescribing of mifepristone. The FDA temporarily removed the requirement that the drug be dispensed in person during the COVID-19 public health emergency in 2021, then finalized that change in 2023 so that a certified prescriber could prescribe after a telehealth visit and a certified pharmacy could fill the prescription by mail or at retail. That revision is what makes a fully remote visit-to-delivery model possible, so a review that reinstated an in-person dispensing step, depending on its scope, would cut against that model.

The case behind the filing

The status report came in State of Louisiana et al. v. FDA. The State of Louisiana, joined by an individual plaintiff, Rosalie Markezich, sued over the policy that lets mifepristone be prescribed by telehealth and sent by mail, naming the FDA, the Department of Health and Human Services, and HHS Secretary Robert F. Kennedy Jr. among the defendants; the drug's manufacturers, Danco Laboratories and GenBioPro, joined as intervenor-defendants. The U.S. District Court for the Western District of Louisiana paused the litigation in the spring of 2026 for about six months while the FDA conducted its review, and set October 7, 2026 as the deadline for the agency to report on the review's status. Louisiana has also taken the dispute to the appeals court, the track covered in our report on the September 9 Fifth Circuit oral argument.

Why access is unchanged right now

No restrictions take effect because of this filing. Telehealth prescribing and mail or pharmacy dispensing remain available nationwide, because the Supreme Court in May 2026 blocked a Fifth Circuit order that would have reinstated the in-person dispensing requirement, and that block holds while the litigation continues. At a hearing last month, a Fifth Circuit panel questioned the merits of Louisiana's case, including whether the state has legal standing to challenge the FDA's dispensing policy. Even a ruling from that panel would not immediately change access, because the Supreme Court's order governs in the meantime.

How the review began

Secretary Kennedy ordered the review, which the FDA has described as a reexamination of the drug's safety record. Reporting on the filing notes that anti-abortion groups and allies in Congress pressed the administration to revisit mifepristone, and that the review followed a report from a conservative think tank asserting a higher rate of serious complications than the FDA had previously recorded; researchers quoted in that reporting disputed the think tank's findings. The projected completion falls months after the November 3, 2026 midterm elections, and some anti-abortion advocates publicly criticized the timeline as too slow.

What this means

For now, nothing changes for clinicians who prescribe mifepristone by telehealth or for patients who receive it by mail. The practical significance of the October 7 filing is a calendar: a study finished around December, a report by March 2027, and a decision on prescribing and distribution rules only after that. The outcome is not set, because the FDA could leave the current rules in place, narrow them, or reinstate an in-person step, and the parallel court tracks could move on their own schedules. Telehealth access to this medication depends less on the video visit than on the dispensing and mailing rules underneath it, which is why an administrative review and a set of court filings, rather than any change to the visit itself, are what could move access.

Practical notes and limits

This article is general information, not medical or legal advice. It summarizes a pending court filing and an ongoing federal review, and it does not predict the outcome or offer guidance on using any medication. The FDA has announced no safety conclusions and no new restrictions. Anyone following the review should rely on the primary court records and the FDA's official REMS materials rather than secondhand summaries, and patients with questions about their care should speak with a licensed clinician. The facts here reflect the record as of the publication date and can change as the review and the litigation proceed.